Figure 3.

RAS pathway mutations and ex vivo cytotoxicity of chemotherapeutic agents. Ex vivo sensitivity of 211 primary patient samples towards (a) prednisolone and (b) vincristine, distinguished by RAS mutation status. Only clonally mutated cases are considered. Only KRAS- and NRAS-mutated groups are shown due to low recurrence of other mutations (see also Supplementary Data). Combined: All cases with a clonal mutation in NRAS, KRAS, PTPN11, FLT3. Groups were compared by Mann–Whitney U-test, *P<0.05, **P<0.01. LC₅₀-values were evaluated by MTT assays as reported previously.